BioSpace News Archive

Drug Development

Stallergenes Greer Announces Publication of Positive Results for PALFORZIA® Phase 3 Study in Peanut-allergic Children Aged 1 to 3 Years

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence.

November 20, 2023
·
6 min read
BioMidwest

Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference

Zomedica Corp. today announced that the management team will attend the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28, 2023.

November 20, 2023
·
1 min read
Pharm Country

Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Merck announced today that Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, is scheduled to participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Thursday, Nov. 30, 2023, at 1:20 p.m. ET.

November 20, 2023
·
3 min read
BioCapital

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

NextCure, Inc. today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30th, at 1:30 pm ET.

November 20, 2023
·
2 min read
Business

Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials

Fortrea today announced a partnership with Medidata to use Medidata AI Intelligent Trials to increase access to diverse patients in clinical trials conducted by Fortrea.

November 20, 2023
·
2 min read
FDA

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

HOOKIPA Pharma Inc. today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV.

November 20, 2023
·
5 min read
Pharm Country

IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio presented data demonstrating that all patients treated with INB-200 who completed mandated doses have exceeded a progression-free survival (PFS) of seven months to date.

November 20, 2023
·
7 min read
Biotech Bay

Gritstone bio to Participate in Upcoming Investor Conferences

Gritstone bio, Inc. today announced that management will be participating in the following investor conferences.

November 20, 2023
·
1 min read
Drug Development

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

ProMIS Neurosciences Inc. today announced that the Company dosed the first subjects in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for Alzheimer’s disease (AD).

November 20, 2023
·
6 min read
Viva Biotech Secures Approximately US$ 210 Million Funding

On November 20, 2023 , Viva Biotech Holdings Group (1873. HK) announced that it completed a funding round, securing approximately US$210 million and bringing in the strategic investors, Temasek, Highlight Capital (HLC), and True Light.

November 20, 2023
·
3 min read